Pharmacologic management of neuropsychiatric lupus

Shaye Kivity, Britain Baker, Maria Teresa Arango, Joab Chapman, Yehuda Shoenfeld

Producción científica: Contribución a una revistaArtículo de revisiónrevisión exhaustiva

4 Citas (Scopus)


Neuropsychiatric lupus affects above 50% of patients with systemic lupus erythematosus and may span from mild symptoms to acute devastating life-threatening ones. Owing to the clinical variability, most pharmacological data rely on small, uncontrolled trials and case reports. The mainstay of therapy relies on immune-suppression by glucocorticoids, in adjunction with cyclophosphamide or anti-B-cell therapy, in moderate to severe cases. In selected scenarios (e.g., chorea) intravenous immunoglobulin or plasmapheresis may be effective. Anticoagulation is warranted if anti-phospholipid antibodies are present. In parallel there may be a need for symptomatic treatment such as anti-epileptic or anti-depressive treatments, etc. In the future, more studies addressed to assess pathogenesis and preferred treatments of specific manifestations are needed in order to personalize treatments
Idioma originalInglés estadounidense
Páginas (desde-hasta)103-108
Número de páginas6
PublicaciónExpert Review of Clinical Pharmacology
EstadoPublicada - ene. 2 2016

Áreas temáticas de ASJC Scopus

  • Farmacología, toxicología y ciencias farmacéuticas (todo)
  • Farmacología (médica)


Profundice en los temas de investigación de 'Pharmacologic management of neuropsychiatric lupus'. En conjunto forman una huella única.

Citar esto